ClinicalTrials.gg
TerminatedNCT01290718Updated Dec 17, 2014Results posted

A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.

A Phase 2 interventional study of capecitabine [Xeloda] and trastuzumab [Herceptin] in Breast Cancer, sponsored by Hoffmann-La Roche. Terminated at 6 sites in Taiwan. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-12-17.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Why this study was terminated
Slow recruitment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 233 studies testing capecitabine in Breast Neoplasms — 32 open to participants now, 41 under way, 10 of them phase 3. Capecitabine · Breast Neoplasms.

Enrollment
214th of 227
4 · median 54
Started
2011
with 5 others
Phase 2
121 of 233
20 open now
Registered
122nd of 233
by date
Lead sponsor
12 of 233
Hoffmann-La Roche

Among the 233 studies testing capecitabine in Breast Neoplasms, this one is the 214th largest by enrollment of the 227 interventional ones that give a count, is one of 6 that started in 2011, is one of 121 in phase 2, and was the 122nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

32 of the 233 studies testing capecitabine in Breast Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 233 studies testing capecitabine in Breast Neoplasms, or all of them as a file.
02

Study summary

This single arm. open-label study will assess the efficacy and safety of Herceptin (trastuzumab) in combination with Xeloda (capecitabine) in patients with metastatic or recurrent HER2-positive breast cancer, refractory to or relapsing after chemotherapy with Herceptin and taxanes. Patients will receive Xeloda 900mg/m2 twice daily orally on days 1-14 of each 3-week cycle and Herceptin 8mg/kg intravenously (iv) on day 1 of the first cycle followed by 6mg/kg iv every 3 weeks. The anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients, 18-65 years of age
  • confirmed -positive breast cancer with (according to criteria)
  • disease after therapy or recurrent disease after (neo) therapy with Herceptin and taxanes
  • performance status 0-2

Exclusion criteria

Exclusion Criteria:

  • which are not well controlled
  • Simultaneous treatment with sorivudine
  • History of another within the last 5 years except for cured basal cell carcinoma of the skin and cured carcinoma in-situ of the uterine cervix
  • Pregnant or lactating women
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Single Arm

    Drug: capecitabine [Xeloda] · Drug: trastuzumab [Herceptin]

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Overall Response

    The tumor response was measured according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria (Version 1.1).

    Time frame: Baseline and Day 1 of Cycles 4 and 8 and every 3 weeks until unacceptable toxicity or Death

Secondary outcomes

  1. Time to Disease Progression

    Tumor response was evaluated according to RECIST criteria (version 1.1). Progressive Disease was defined as at least a 20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Time to progression is the time from the date of first dose of drug administration to the date when first disease progression is recorded.

    Time frame: Baseline and Day 1 of Cycles 4 and 8 and every 3 weeks until unacceptable toxicity or Death

  2. Overall Survival

    Overall survival (OS) is the time from the date of randomization to the date of death irrespective of the cause of death.

    Time frame: Baseline and Day 1 of Cycles 4 and 8 and every 3 weeks until unacceptable toxicity or Death

  3. Progression-Free Survival

    Tumor response was evaluated according to RECIST criteria (version 1.1). Progressive Disease was defined as at least a 20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Participants without progression were censored at the date of last tumor assessment when non progression was documented.

    Time frame: Baseline and Day 1 of Cycles 4 and 8 and every 3 weeks until unacceptable toxicity or Death

07

Results

Posted Dec 17, 2014

Participant flow

Participant flow — Overall Study
MilestoneCapecitabine Plus (+) Trastuzumab
Started4
Completed0
Not completed4
Withdrew: Early termination of the study4

Outcome measures

PrimaryPercentage of Participants With Overall Response

The tumor response was measured according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria (Version 1.1).

Time frame:
Baseline and Day 1 of Cycles 4 and 8 and every 3 weeks until unacceptable toxicity or Death

No measurements were reported for this outcome.

SecondaryTime to Disease Progression

Tumor response was evaluated according to RECIST criteria (version 1.1). Progressive Disease was defined as at least a 20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Time to progression is the time from the date of first dose of drug administration to the date when first disease progression is recorded.

Time frame:
Baseline and Day 1 of Cycles 4 and 8 and every 3 weeks until unacceptable toxicity or Death

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival (OS) is the time from the date of randomization to the date of death irrespective of the cause of death.

Time frame:
Baseline and Day 1 of Cycles 4 and 8 and every 3 weeks until unacceptable toxicity or Death

No measurements were reported for this outcome.

SecondaryProgression-Free Survival

Tumor response was evaluated according to RECIST criteria (version 1.1). Progressive Disease was defined as at least a 20% increase in the sum of LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Participants without progression were censored at the date of last tumor assessment when non progression was documented.

Time frame:
Baseline and Day 1 of Cycles 4 and 8 and every 3 weeks until unacceptable toxicity or Death

No measurements were reported for this outcome.

Adverse events

Collected over Adverse events (AEs) occurring up to 28 days after the last dose of study medication were to be reported.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capecitabine + Trastuzumab—0/2 (0%)0/2 (0%)

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Capecitabine + Trastuzumab
Mean53.75 ± 9.03
Sex: Female, Male
Sex: Female, Male(Participants)Capecitabine + Trastuzumab
Female4
Male0
08

Study locations

6 sites
  • Chai Yi, 613, Taiwan
  • Kaohsiung, 807, Taiwan
  • Taipei, 00112, Taiwan
  • Taipei, 100, Taiwan
  • Taipei, 105, Taiwan
  • Taipei, 112, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2011
First posted
Feb 7, 2011
Start
Dec 2011
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Results first posted
Dec 17, 2014
Last update
Dec 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01290718
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 7, 2011
Start date
Dec 2011
Primary completion
Dec 2012
Completion
Dec 2012
Results posted
Dec 17, 2014
Last update
Dec 17, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Trastuzumab

Start the discussion